This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Dermatology  • Dermatology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Jean-Paul Ortonne, MD; Francisco Camacho-Martinez, MD; Derek Freedman, MD; Andreas Katsambas, MD; Frank Powell, MD; Diane Roseeuw, MD; Torello Lotti, MD; Willem van Vloten, MD
From the Departments of Dermatology, l'Hôpital Archet, University of Nice, Nice, France (Dr Ortonne), and University of Sevilla, Sevilla, Spain (Dr Camacho-Martinez); St James Hospital, Dublin, Ireland (Dr Freedman); Sygros Hospital, University of Athens, Athens, Greece (Dr Katsambas); Regional Center of Dermatology, Mater Misericordiae Hospital, Dublin (Dr Powell); and Departments of Dermatology, Akademisch Ziekenhuis VUB, Brussels, Belgium (Dr Roseeuw), University of Florence, Florence, Italy (Dr Torello), and University Medical Center Utrecht, Utrecht, the Netherlands (Dr van Vloten).

Arch Dermatol. 2000;136:308-310.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Dr Martino Neumann's article in the ARCHIVES, "Is Pharmaceutical Sponsorship of a Dermatologic Conference Proper?"¹ raises important, well-established, and obvious issues of concern to all dermatologists as well as physicians in general. The relationship between the pharmaceutical and allied health industries and the medical profession needs constant and careful scrutiny to avoid the potential for compromise of science by commerce. The objectives of both are not mutually exclusive, and no one can ignore the fact that the many excellent therapies available to patients are a credit to the time and finances invested by these industries in research and development of new products. Physicians need to be informed about these products when they become available, and the sharing of this information is part of the legitimate . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Shadow of a Doubt
Jose M. Mascaro
Arch Dermatol. 2000;136(3):310-311.
EXTRACT | FULL TEXT  

In Reply
H. A. Martino Neumann
Arch Dermatol. 2000;136(3):311.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

In Reply
Martino Neumann
Arch Dermatol 2000;136:311-311.
FULL TEXT